A randomized, open-label, phase III study (OlympiAD) [68] compared the efficacy of olaparib monotherapy with that of physician’s choice of monotherapy in patients with a germline BRCA1/2-mutated and HER2-negative metastatic BC, with progression-free survival (PFS) as the primary endpoint. This evidence concerns the gene BRCA1 and breast cancer.